| Yesterday | ||||
RBC Capital analyst… RBC Capital analyst Charles Weston upgraded Lonza to Outperform from Sector Perform with a price target of CHF 650, down from CHF 720. The analyst expects supply and demand for biologic contract development and manufacturing will be "tightly matched" for through 2024 and says demand should then "materially exceed" supply from 2025. This de-risks long-term growth forecasts for Lonza, Weston tells investors in a research note. | ||||
| Thursday | ||||
Kodiak Sciences (KOD) and… Kodiak Sciences (KOD) and Lonza (LZAGY) announced the opening of a new, custom-built, bioconjugation facility within Lonza's Ibex Dedicate manufacturing complex in Visp. The facility will play a key role in the scaled manufacturing of Kodiak's lead therapeutic candidate KSI-301 to support a potential global commercial launch. Once fully operational and if KSI-301 is approved for commercial use, the facility is expected to have the capacity to supply over 10 million dose equivalents of KSI-301 annually. The strong relationship between Kodiak and Lonza has led to a multi-year commercial collaboration that has created 12 full-time positions at Kodiak Sciences in Visp and 70 positions at Lonza. | ||||
| Over a month ago | ||||
Morgan Stanley analyst… Morgan Stanley analyst James Quigley lowered the firm's price target on Lonza to CHF 785 from CHF 800 and keeps an Equal Weight rating on the shares. | ||||
| Over a quarter ago | ||||
Stifel analyst Bruno… Stifel analyst Bruno Bulic upgraded Lonza to Buy from Hold with a price target of CHF 838, up from CHF 785, after taking over coverage of the name. The analyst has a positive view on the evolution of Lonza's margins and the upside from its biologics division, in particular the biosimilar segment. | ||||
JPMorgan analyst Richard… JPMorgan analyst Richard Vosser raised the firm's price target on Lonza to CHF 900 from CHF 850 and keeps an Overweight rating on the shares. | ||||
Lonza (LZAGY) announced… Lonza (LZAGY) announced the acquisition of an exosome manufacturing facility located in Lexington, Massachusetts from Codiak BioSciences (CDAK). Codiak will retain its pipeline of therapeutic candidates as well as its exosome engineering and drug-loading technologies. Codiak will receive as part of the deal approximately $65M of cGMP manufacturing services in kind. Lonza will gain worldwide access and sub-licensable rights to Codiak's high-throughput perfusion-based cGMP process for exosome manufacturing. The companies will establish a Center of Excellence for the development of exosome manufacturing technologies. Alberto Santagostino, SVP, Head of Cell and Gene Technologies at Lonza, commented: "We are excited about the collaboration we have established with Codiak BioSciences. Exosomes are emerging as a new modality for advanced therapies and could become the next frontier in biotherapeutics. Our collaboration with Codiak, one of the most advanced companies in this modality, is consistent with our strategy to advance this technology and will drive the advancement of the whole industry. We are committed to providing our capabilities to Codiak, alongside other customers in the exosome space." | |
UBS analyst Patrick… UBS analyst Patrick Rafaisz upgraded Lonza to Buy from Neutral with a price target of CHF 830, up from CHF 610. The analyst sees a "compelling long-term growth story" and sees opportunity following the recent pullback in the shares. He views Lonza's valuation as attractive at current levels. | |
Deutsche Bank analyst… Deutsche Bank analyst Falko Friedrichs raised the firm's price target on Lonza to CHF 835 from CHF 800 and keeps a Buy rating on the shares. | |
Morgan Stanley analyst… Morgan Stanley analyst James Quigley downgraded Lonza to Equal Weight from Overweight with a price target of CHF 810, up from CHF 745. | |
JPMorgan analyst Richard… JPMorgan analyst Richard Vosser raised the firm's price target on Lonza to CHF 850 from CHF 680 and keeps an Overweight rating on the shares. |
